Literature DB >> 10856323

Alpha-1-antitrypsin deficiency: what next?

R A Stockley1.   

Abstract

Entities:  

Mesh：

Year:  2000        PMID： 10856323      PMCID： PMC1745789          DOI： 10.1136/thorax.55.7.614

Source DB:  PubMed          Journal:  Thorax        ISSN： 0040-6376            Impact factor:   9.139


× No keyword cloud information.
  22 in total

1.  Augmentation therapy for severe alpha 1-antitrypsin deficiency: is the jury still out on a trial?

Authors:  J K Stoller
Journal:  Thorax       Date:  1998-12       Impact factor: 9.139

2.  A randomized clinical trial of alpha(1)-antitrypsin augmentation therapy.

Authors:  A Dirksen; J H Dijkman; F Madsen; B Stoel; D C Hutchison; C S Ulrik; L T Skovgaard; A Kok-Jensen; A Rudolphus; N Seersholm; H A Vrooman; J H Reiber; N C Hansen; T Heckscher; K Viskum; J Stolk
Journal:  Am J Respir Crit Care Med       Date:  1999-11       Impact factor: 21.405

3.  Determinants of health-related quality of life in patients with chronic obstructive pulmonary disease.

Authors:  C A Ketelaars; M A Schlösser; R Mostert; H Huyer Abu-Saad; R J Halfens; E F Wouters
Journal:  Thorax       Date:  1996-01       Impact factor: 9.139

4.  Does alpha1-antitrypsin augmentation therapy slow the annual decline in FEV1 in patients with severe hereditary alpha1-antitrypsin deficiency? Wissenschaftliche Arbeitsgemeinschaft zur Therapie von Lungenerkrankungen (WATL) alpha1-AT study group.

Authors:  N Seersholm; M Wencker; N Banik; K Viskum; A Dirksen; A Kok-Jensen; N Konietzko
Journal:  Eur Respir J       Date:  1997-10       Impact factor: 16.671

5.  Effects of an immunostimulating agent on acute exacerbations and hospitalizations in patients with chronic obstructive pulmonary disease. The PARI-IS Study Steering Committee and Research Group. Prevention of Acute Respiratory Infection by an Immunostimulant.

Authors:  J P Collet; P Shapiro; P Ernst; T Renzi; T Ducruet; A Robinson
Journal:  Am J Respir Crit Care Med       Date:  1997-12       Impact factor: 21.405

6.  Effect of age and occupational exposure to airway irritants on lung function in non-smoking individuals with alpha 1-antitrypsin deficiency (PiZZ).

Authors:  E Piitulainen; G Tornling; S Eriksson
Journal:  Thorax       Date:  1997-03       Impact factor: 9.139

7.  Clinical features of individuals with PI*SZ phenotype of alpha 1-antitrypsin deficiency. alpha 1-Antitrypsin Deficiency Registry Study Group.

Authors:  G M Turino; A F Barker; M L Brantly; A B Cohen; R P Connelly; R G Crystal; E Eden; M D Schluchter; J K Stoller
Journal:  Am J Respir Crit Care Med       Date:  1996-12       Impact factor: 21.405

8.  Quantum proteolysis resulting from release of single granules by human neutrophils: a novel, nonoxidative mechanism of extracellular proteolytic activity.

Authors:  T G Liou; E J Campbell
Journal:  J Immunol       Date:  1996-09-15       Impact factor: 5.422

9.  Nonisotropic enzyme--inhibitor interactions: a novel nonoxidative mechanism for quantum proteolysis by human neutrophils.

Authors:  T G Liou; E J Campbell
Journal:  Biochemistry       Date:  1995-12-12       Impact factor: 3.162

10.  Preliminary evidence that augmentation therapy diminishes degradation of cross-linked elastin in alpha-1-antitrypsin-deficient humans.

Authors:  P J Stone; T A Morris; C Franzblau; G L Snider
Journal:  Respiration       Date:  1995       Impact factor: 3.580
View more
  4 in total

1.  Correlation between annual change in health status and computer tomography derived lung density in subjects with alpha1-antitrypsin deficiency.

Authors:  J Stolk; W H Ng; M E Bakker; J H C Reiber; K F Rabe; H Putter; B C Stoel
Journal:  Thorax       Date:  2003-12       Impact factor: 9.139

2.  Prolastin, a pharmaceutical preparation of purified human alpha1-antitrypsin, blocks endotoxin-mediated cytokine release.

Authors:  Izabela Nita; Camilla Hollander; Ulla Westin; Sabina-Marija Janciauskiene
Journal:  Respir Res       Date:  2005-01-31

3.  Selected metabolic aspects of elastin and collagen fiber proteolysis in diseases of the respiratory system - the significance of α1 antitrypsin deficiency.

Authors:  Agata Dżeljilji; Wojciech Rokicki; Krzysztof Karuś
Journal:  Kardiochir Torakochirurgia Pol       Date:  2016-09-30

Review 4.  Alpha 1 antitrypsin to treat lung disease in alpha 1 antitrypsin deficiency: recent developments and clinical implications.

Authors:  Kenneth R Chapman; Joanna Chorostowska-Wynimko; A Rembert Koczulla; Ilaria Ferrarotti; Noel G McElvaney
Journal:  Int J Chron Obstruct Pulmon Dis       Date:  2018-01-31
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.